Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults

E. Ludwig, S. Ünal, M. Bogdan, R. Chlíbek, Y. Ivanov, R. Kozlov, H. Lode, Z. Mészner, R. Prymula, G. Rahav, A. Skoczyńska, I. Solovič, A. Sayiner

. 2013 ; 21 (4) : 233-237.

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc14056229

BACKGROUND: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. DISCUSSION: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agenda of national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and the future place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. RESULTS: The use of conjugate vaccine induces immunological memory and can overcome some limitations associated with the plain polysaccharide vaccine (PPV). It was also agreed that, if the use of PPV is considered appropriate, PCV13 should be administered first, regardless of prior pneumococcal vaccination status.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14056229
003      
CZ-PrNML
005      
20250424083625.0
007      
ta
008      
140415s2013 xr f 000 0|eng||
009      
AR
024    7_
$a 10.21101/cejph.a3959 $2 doi
035    __
$a (PubMed)24592732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ludwig, Endre $7 _AN078053 $u Division of Infectious Diseases, Department of Internal Medicine No. II, Semmelweis Medical University, Budapest, Hungary
245    10
$a Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults / $c E. Ludwig, S. Ünal, M. Bogdan, R. Chlíbek, Y. Ivanov, R. Kozlov, H. Lode, Z. Mészner, R. Prymula, G. Rahav, A. Skoczyńska, I. Solovič, A. Sayiner
520    9_
$a BACKGROUND: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. DISCUSSION: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agenda of national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and the future place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. RESULTS: The use of conjugate vaccine induces immunological memory and can overcome some limitations associated with the plain polysaccharide vaccine (PPV). It was also agreed that, if the use of PPV is considered appropriate, PCV13 should be administered first, regardless of prior pneumococcal vaccination status.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pneumokokové infekce $x imunologie $x prevence a kontrola $7 D011008
650    _2
$a pneumokokové vakcíny $x aplikace a dávkování $x imunologie $7 D022242
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
651    _2
$a Evropa $7 D005060
651    _2
$a Izrael $7 D007557
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ünal, Serhat $7 _AN078054 $u Section of Infectious Diseases, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
700    1_
$a Bogdan, Miron $7 xx0331424 $u Carol Davila University of Medicine, Bucharest and Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania
700    1_
$a Chlíbek, Roman, $d 1965- $7 mzk2003191937 $u Department of Epidemiology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
700    1_
$a Ivanov, Yavor $7 _AN078056 $u Pulmonology and Phthisiatry Clinic, University Hospital, Pleven, Bulgaria
700    1_
$a Kozlov, Roman $7 _AN078057 $u Institute of Antimicrobial Chemotherapy, Smolensk State Medical Academy, Smolensk, Russia
700    1_
$a Lode, Hartmut $7 nlk20050167092 $u Research Center of Medical Studies (RCMS), Institute for Clinical Pharmacology, Charité University Medicine of Berlin, Berlin, Germany
700    1_
$a Mészner, Zsófia $7 _AN078058 $u National Institute of Child Health, Szent Laszlo Hospital for Infectious Diseases, Budapest, Hungary
700    1_
$a Prymula, Roman, $d 1964- $7 nlk19990073741 $u University Hospital, Hradec Králové, Czech Republic
700    1_
$a Rahav, Galia $7 _AN078059 $u Infectious Disease Unit, Sheba Medical Centre, Tel Hashomer, Ramat-Gan, Israel
700    1_
$a Skoczyńska, Anna $7 _AN078060 $u National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
700    1_
$a Solovič, Ivan $7 xx0096396 $u Pulmonology Department of National Institute for TB, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Catholic University, Ružomberok, Slovakia
700    1_
$a Sayiner, Abdullah $7 _AN078061 $u Department of Chest Diseases, Ege University Medical Faculty, Izmir, Turkey
773    0_
$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 21, č. 4 (2013), s. 233-237
856    41
$u https://cejph.szu.cz/pdfs/cjp/2013/04/11.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 1829 $c 562 $y 4 $z 0
990    __
$a 20140415 $b ABA008
991    __
$a 20250424083624 $b ABA008
999    __
$a ok $b bmc $g 1025409 $s 854823
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 21 $c 4 $d 233-237 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
LZP    __
$b NLK118 $a Pubmed-20140415

Find record

Citation metrics

Archiving options